BioVaxys Technology Corp. BVAXF

Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp. > BIOV ANNOUNCE COMPLETED PVT & DEBT SETTLEMENT

<< Previous

Bullboard Posts

Next >>

Comment by moneywagonon Nov 10, 2022 9:11am

47 Views

Post# 35087877

RE:BIOV ANNOUNCE COMPLETED PVT & DEBT SETTLEMENT

Good morning Humanist...thanks for contributing, yup its an update on date, old newswire with GREAT PROGRESS!! Yahooo absolutely excited to see that...but again the sp of pp is ole ole news!!

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions